Gilead Sciences, Inc.

NASDAQ:GILD   3:59:59 PM EDT
66.54
+0.03 (+0.04%)
5:01:07 PM EDT: $66.54 0.00 (0.00%)
Products, Strategic Combinations

Matinas Biopharma Announces Collaboration With National Institute Of Allergy And Infectious Diseases To Evaluate Oral Formulations Of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platfor

Published: 12/07/2020 11:50 GMT
Gilead Sciences, Inc. (GILD) - Matinas Biopharma Announces Collaboration With the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ Lnc Platform Delivery Technology.
Matinas Biopharma - Any Product Generated As a Part of Efforts by Matinas and Niaid Would Require a License From Gilead for Use of Remdesivir.
Matinas Biopharma - Any Product Generated As a Part of Efforts by Matinas and Niaid Would Require License From Matinas for Use of Lnc Formulation.